Frontiers in Medical Science Research, 2022, 4(4); doi: 10.25236/FMSR.2022.040406.
Ruopeng Wang1, Shuyan Li2, Leyu Wang3
1Soochow University, Suzhou, Jiangsu, China
2China Pharmaceutical University, Nanjing, Jiangsu, China
3Zhejiang University, Hangzhou, Zhejiang, China
These authors contributed equally to this work
The aim of this study was to design a panel of gene polymorphism detection of MAFLD in East Asian population based on current research. Literature search was conducted in PubMed database using the keywords "metabolism-related fatty liver" or "non-alcoholic fatty liver" and "Asia" or "East Asia" and "gene”. 41 studies met the inclusion criteria, and 12 key genetic loci were screened out involving FTO, KLB, PNPLA3, TRIB1, PPARα, LEPR, APOA5, TM6SF2, APOC3, GCKR, SREBP2, MTTP, associating with obesity, insulin resistance, glucose metabolism, fatty acid metabolism, and inflammatory fibrosis pathways. The panel was designed successfully, while the sensitivity and specificity remain to be further clinically validated.
Panel, Metabolic dysfunction-associated fatty liver disease, MAFLD, Gene, East Asian
Ruopeng Wang, Shuyan Li, Leyu Wang. A panel design of gene polymorphism detection of metabolic dysfunction-associated fatty liver disease in East Asian population. Frontiers in Medical Science Research (2022) Vol. 4, Issue 4: 36-43. https://doi.org/10.25236/FMSR.2022.040406.
[1] Eslam, M., et al., A new definition for metabolic dysfunction-associated fatty liver disease: An international expert consensus statement. J Hepatol, 2020. 73(1): p. 202-209.
[2] Huang, D.Q., H.B. El-Serag, and R. Loomba, Global epidemiology of NAFLD-related HCC: trends, predictions, risk factors and prevention. Nat Rev Gastroenterol Hepatol, 2021. 18(4): p. 223-238.
[3] Benedict, M. and X. Zhang, Non-alcoholic fatty liver disease: An expanded review. World J Hepatol, 2017. 9(16): p. 715-732.
[4] Bugianesi, E., et al., Insulin resistance in nonalcoholic fatty liver disease. Curr Pharm Des, 2010. 16(17): p. 1941-51.
[5] Federico, A., et al., Targeting gut-liver axis for the treatment of nonalcoholic steatohepatitis: translational and clinical evidence. Transl Res, 2016. 167(1): p. 116-24.
[6] Anstee, Q.M. and C.P. Day, The Genetics of Nonalcoholic Fatty Liver Disease: Spotlight on PNPLA3 and TM6SF2. Semin Liver Dis, 2015. 35(3): p. 270-90.
[7] Guerrero, R., et al., Ethnic differences in hepatic steatosis: an insulin resistance paradox? Hepatology, 2009. 49(3): p. 791-801.
[8] Bambha, K., et al., Ethnicity and nonalcoholic fatty liver disease. Hepatology, 2012. 55(3): p. 769-80.
[9] Guo, J., et al., Fat mass and obesity-associated gene enhances oxidative stress and lipogenesis in nonalcoholic fatty liver disease. Dig Dis Sci, 2013. 58(4): p. 1004-9.
[10] Lee, S., et al., Structures of β-klotho reveal a 'zip code'-like mechanism for endocrine FGF signalling. Nature, 2018. 553(7689): p. 501-505.
[11] Gijón, M.A., et al., Lysophospholipid acyltransferases and arachidonate recycling in human neutrophils. J Biol Chem, 2008. 283(44): p. 30235-45.
[12] Eshraghian, A., S. Iravani, and P. Azimzadeh, The Association between Angiotensin II Type 1 Receptor Gene A1166C Polymorphism and Non-alcoholic Fatty Liver Disease and Its Severity. Middle East J Dig Dis, 2018. 10(2): p. 96-104.
[13] Yoshiji, H., et al., Angiotensin-II type 1 receptor interaction is a major regulator for liver fibrosis development in rats. Hepatology, 2001. 34(4 Pt 1): p. 745-50.
[14] Gottlieb, M.G., et al., Association between the Gln223Arg polymorphism of the leptin receptor and metabolic syndrome in free-living community elderly. Metab Syndr Relat Disord, 2009. 7(4): p. 341-8.
[15] Tsuzaki, K., et al., The relationship between adiponectin, an adiponectin gene polymorphism, and high-density lipoprotein particle size: from the Mima study. Metabolism, 2012. 61(1): p. 17-21.
[16] Saxena, R., et al., Large-scale gene-centric meta-analysis across 39 studies identifies type 2 diabetes loci. Am J Hum Genet, 2012. 90(3): p. 410-25.
[17] Petersen, K.F., et al., Apolipoprotein C3 gene variants in nonalcoholic fatty liver disease. N Engl J Med, 2010. 362(12): p. 1082-9.
[18] Zain, S.M., Z. Mohamed, and R. Mohamed, Common variant in the glucokinase regulatory gene rs780094 and risk of nonalcoholic fatty liver disease: a meta-analysis. J Gastroenterol Hepatol, 2015. 30(1): p. 21-7.
[19] Bommer, G.T. and O.A. MacDougald, Regulation of lipid homeostasis by the bifunctional SREBF2-miR33a locus. Cell Metab, 2011. 13(3): p. 241-7.
[20] Zheng, W., et al., MTP - 493G>T polymorphism and susceptibility to nonalcoholic fatty liver disease: a meta-analysis. DNA Cell Biol, 2014. 33(6): p. 361-9.
[21] Zeng, F., et al., Predicting Non-Alcoholic Fatty Liver Disease Progression and Immune Deregulations by Specific Gene Expression Patterns. Front Immunol, 2020. 11: p. 609900.